<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886195</url>
  </required_header>
  <id_info>
    <org_study_id>secgolc001</org_study_id>
    <nct_id>NCT02886195</nct_id>
  </id_info>
  <brief_title>EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC</brief_title>
  <acronym>effect</acronym>
  <official_title>EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to compare the efficacy of EGFR-TKIs(Epidermal Growth Factor
      Receptor-Tyrosine Kinase Inhibitors) treatment plus concurrent chemotherapy versus sequential
      treatment with EGFR-TKIs and chemotherapy in patients with EGFR(Epidermal Growth Factor
      Receptor)-mutant non-small-cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, parallel-group controlled clinical trial, and the study
      subjects recruited in this study are NSCLC patients mutant for EGFR gene (19del or L858R).

      Subjects in the concurrent therapy group were given EGFR-TKIs treatment plus concurrent
      chemotherapy. Patients in the sequential treatment group were assigned to sequential
      EGFR-TKIs followed by chemotherapy group, which received TKIs monotherapy and then
      chemotherapy alone after disease progression; and sequential chemotherapy followed by
      EGFR-TKIs treatment, which was given first-line chemotherapy for 4 to 6 cycles, followed by
      maintenance therapy with EGFR-TKIs.

      The endpoint of this study included clinical efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE)</measure>
    <time_frame>2 months</time_frame>
    <description>NCI CTC 4.03</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>EGFR Gene Mutation</condition>
  <arm_group>
    <arm_group_label>PC plus erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1; concurrent erlotinib 150mg/d d1-21, per 3 week, for 4-6cycles, then erlotinib 150mg/d maintain therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>erlotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>erlotinib 150mg/d until &quot;progress disease&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1 for 4-6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>500mg/m2 ivgtt d1, per three weeks</description>
    <arm_group_label>PC plus erlotinib</arm_group_label>
    <arm_group_label>PC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>80mg/m2 ivgtt d1, per three weeks</description>
    <arm_group_label>PC plus erlotinib</arm_group_label>
    <arm_group_label>PC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150mg po. every day</description>
    <arm_group_label>PC plus erlotinib</arm_group_label>
    <arm_group_label>erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage â…£ EGFR mutation-positive NSCLC

          -  Initial therapy

          -  ECOG performance status 0-1

        Exclusion Criteria:

          -  EGFR mutation-negative

          -  Previous systemic antitumour treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhiyong he he, master</last_name>
    <role>Study Chair</role>
    <affiliation>Fujian province cancer hospital</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>August 27, 2016</last_update_submitted>
  <last_update_submitted_qc>August 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Depending on the process of the study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

